Evaluation of leptin treatment on maintenance of body weight loss in diet‐induced obese mice
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Danna M Breen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Research Unit, Pfizer Research & Development, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Leptin, Obesity, Weight Loss, Anti-Obesity Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
To evaluate the therapeutic potential of leptin treatment for weight loss maintenance preclinically, through a systematic evaluation of leptin efficacy (a) following a period of weight loss stability (as in published clinical studies), and (b) across a range of circulating leptin concentrations achieved through a variety of different weight loss conditions. Materials/Methods Body weight and plasma leptin reduction were achieved via caloric restriction in diet‐induced obese (DIO) male mice. The effect of r‐Leptin (pulsatile exposure) or Fc‐Leptin (continuous exposure), administered centrally or systemically, on the prevention of weight regain was tested in a variety of conditions aimed at lowering circulating leptin levels: following 10% or 20% weight loss, with or without a prior weight loss stabilization period, or dietary fat reduction from 60% to 30%.
Results
Leptin treatment (physiological to pharmacological dose ranges) did not prevent weight regain in the 10% weight loss (30% leptin lowering) model with or without a weight loss stabilization period. In contrast, liraglutide was effective in maintaining weight loss. Continuous high CNS leptin exposure targeting up to 35 nM (585 ng/mL) in CSF via intracerebroventricular infusion maintained weight loss in non‐obese chow‐fed mice but was ineffective in DIO mice. Lowering circulating leptin to non‐obese mouse concentrations via either achieving greater weight loss (20%) or reducing dietary fat content (60% to 30%) was also not sufficient to reveal a leptin benefit on weight regain.
Conclusions
Leptin treatment is not sufficient to maintain caloric restriction‐induced weight loss in preclinical models and does not support the theory that leptin resistance in obesity is due to excessive leptin production and saturation of leptin signalling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Research Unit, Pfizer Research & Development, Cambridge, Massachusetts, USA.
- Biostatistics, Early Clinical Development, Pfizer Research & Development, Cambridge, Massachusetts, USA.
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Global R&D, La Jolla, California, USA.
ORCID-Profile: Rocío M Saavedra-Peña, J Brent Kuzmiski
Zitieren
APA
Breen, D. M., Saavedra-Peña, R. M., Joaquim, S., Kong, J., Reese, R., Kuzmiski, J. B., Stansfield, J. C., Jones, R., Bence, K. K., & Jackson, V. M. (2026). Evaluation of leptin treatment on maintenance of body weight loss in diet‐induced obese mice. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70207
Vancouver
Breen DM, Saavedra-Peña RM, Joaquim S, Kong J, Reese R, Kuzmiski JB, et al. Evaluation of leptin treatment on maintenance of body weight loss in diet‐induced obese mice. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70207
BibTeX
@article{Breen2026,
author = {Breen, Danna M and Saavedra-Peña, Rocío M and Joaquim, Stephanie and Kong, Jimmy and Reese, Ryan and Kuzmiski, J Brent and Stansfield, John C and Jones, Rhys and Bence, Kendra K and Jackson, V Margaret},
title = {Evaluation of leptin treatment on maintenance of body weight loss in diet‐induced obese mice},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70207}
}
EUVIMED